FDA Approves Jascayd/Nerandomilast for Progressive Pulmonary Fibrosis
The US FDA has approved Jascayd (nerandomilast) tablets for the treatment of progressive pulmonary fibrosis (PPF) in adults, according to Boehringer Ingelheim.
Tag: nerandomilast Jascayd
FDA Approves Jascayd/Nerandomilast for Progressive Pulmonary Fibrosis
The US FDA has approved Jascayd (nerandomilast) tablets for the treatment of progressive pulmonary fibrosis (PPF) in adults, according to Boehringer Ingelheim.
Read More
Jascayd/Nerandomilast Slowed FVC Decline in IPF
Addition of Nerandomilast (Jascayd) to a treatment regimen for patients receiving standard of care therapy for idiopathic pulmonary fibrosis may slow disease progression.
Read More
FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis
The US FDA approved Jascayd (nerandomilast) tablets to treat idiopathic pulmonary fibrosis (IPF), the first new therapy approved in more than 10 years for IPF.
Read More
Positive Data for Nerandomilast in IPF/PPF
Boehringer Ingelheim revealed new data from two Phase 3 clinical trials on Nerandomilast, an investigational orally-administered drug candidate for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF).
Read More